Sells medicines for dependence, mental health conditions and narcolepsy to pharmaceutical wholesalers, pharmacies and treatment providers.
10-K for FY2025, filed Feb 25, 2026Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a…View ↗
We are responsible for the marketing of ARISTADA, ARISTADA INITIO, LYBALVI, LUMRYZ and VIVITROL in the U.S. We focus our sales and…View ↗
Our sales force for VIVITROL in the U.S. consisted of approximately 105 individuals as of December 31, 2025. VIVITROL is primarily sold to…View ↗
Our sales force for LUMRYZ in the U.S. became a part of the Company in February 2026 when we completed the Avadel Acquisition. As of the…View ↗
Alkermes earns product-sale revenue when customers receive its medicines. It earns manufacturing revenue when products are fully made and royalties when licensees sell products using its technologies or license its product.
10-K for FY2025, filed Feb 25, 2026The Company’s product sales, net in 2025 and 2024 consisted of sales in the U.S. of ARISTADA®, ARISTADA INITIO® LYBALVI® and VIVITROL®…View ↗
Substantially all of our manufacturing revenue was recognized at the point in time that the product has been fully manufactured. Royalties…View ↗
We have licensed products to third parties for commercialization and have licensed our proprietary technologies to third parties to enable…View ↗
$1.5B
10-K for FY2025, filed Feb 25, 2026
$1.5B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
80%
FY2022: 70%
|
Product sales, net, FY2025
$1.2B Sources
|
Sold outright |
|
Manufacturing and royalty revenues
Mix
10-K for FY2025, filed Feb 25, 2026 |
20%
FY2022: 30%
|
Manufacturing and royalty revenues, FY2025
$291.3M Sources
|
Mix |
Alkermes sells its U.S. medicines mainly to pharmaceutical wholesalers, specialty distributors and pharmacies; VIVITROL also goes to treatment providers. Licensees commercialize products covered by their agreements.
10-K for FY2025, filed Feb 25, 2026Our sales force for VIVITROL in the U.S. consisted of approximately 105 individuals as of December 31, 2025. VIVITROL is primarily sold to…View ↗
Our sales force for ARISTADA, ARISTADA INITIO and LYBALVI in the U.S. consisted of approximately 435 individuals as of December 31, 2025.…View ↗
Our sales force for LUMRYZ in the U.S. became a part of the Company in February 2026 when we completed the Avadel Acquisition. As of the…View ↗
Under our license agreements with Janssen, Biogen and other licensees and sublicensees, the licensees and sublicensees are typically…View ↗
Yes. It kept 16 cents of every revenue dollar as net income in FY2025 and turned 33 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of…View ↗
Growing. Revenue grew 26% in 4 years, from $1.2B in FY2021 to $1.5B in FY2025, about 6% a year.
Added narcolepsy treatment
The latest report adds LUMRYZ, a narcolepsy medicine, to the proprietary commercial portfolio; the older report described proprietary products focused on dependence, schizophrenia and bipolar I disorder.
10-K for FY2022, filed Feb 16, 2023 10-K for FY2025, filed Feb 25, 2026Alkermes plc is a fully-integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to…View ↗
Competes with Teva, Lilly, Luye Pharma Group, MedinCell, Lupin, Amneal Pharmaceuticals, Johnson & Johnson, Abbvie, Bristol-Myers Squibb, Indivior, BioDelivery Sciences, Orexo US, Braeburn, Genentech, Bayer HealthCare Pharmaceuticals, EMD Serono, Novartis, Sanofi-Aventis, Axsome Therapeutics, and Harmony Biosciences Holdings
10-K for FY2025, filed Feb 25, 2026With respect to our proprietary injectable product platform, we are aware that there are other companies developing extended-release…View ↗
Loading...